Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US11608369B2 · kind B2 · utility
3Cited by
8References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2022 |
| Grant date | Mar 21, 2023 |
| Priority date | — |
| Expiry date | May 23, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.